Wall Street fawns over the companies listed in today's table. So why do our Motley Fool CAPS members disagree? They've tarred these stocks with one- and two-star ratings, showing a lack of faith that the associated companies will outperform the market.
So who has it right? The professional class of analysts sitting in their paneled offices smoking stogies, or a motley crew of community investors pooling their best thoughts for others to share? We think we know who'll come out ahead. How about you?
CAPS Rating (out of 5)
Wall Street Bullish Sentiment
Source: Motley Fool CAPS.
Now as much as we love our CAPS community, don't sell these companies just because they've garnered low ratings. And don't buy 'em just because Wall Street says to either. Investing requires closer diligence on your part, so use these ratings as a launching pad for your own research.
Still huffing and puffing
Doesn't anyone want to make computers anymore? Hewlett-Packard's
Some might point to Dell as a computer maker still, but even there the focus has largely shifted away from desktops (and even laptops) and focused more on software and business services. The analysts at Trefis peg Dell's computer business at just 18% of the company's value while managed services, consulting, and Perot account for 21%.
If imitation is the sincerest form of flattery, then IBM must be feeling particularly puffed up as both HP and Dell follow its lead out of the computer business. Of course, that leaves the field primarily to Apple
Leaving when you're on top is always a valued strategy, one that HP is apparently following. It's currently the largest PC maker with 18% global market share, followed by Dell at 12.9%. With Lenovo close on Dell's heels with a 12.2% share, it won't be long before it overtakes it for the No. 2 spot and effectively allowing it to assume the mantle of largest computer maker when HP bows out.
Tell us on the Dell CAPS page whether you think it can recover its once dominant position in the industry or should it continue down the path HP and IBM have taken.
A rare breed
I like it when an insider buys his stock. I like it doubly so when the CFO does it since he's got his finger on the pulse of what makes his company grow. But what do you do when there's an orgy of insider buying? If you're CAPS member dcsilver, you buy right alongside them!
He notes that antiviral maker Novavax is currently suffering from a surfeit of insider buying. From the president and CEO to the CFO and treasurer, insiders have been scooping up shares of Novavax stock.
Forget the company, forget what they do for a second, forget that shares of NVAX are down despite positive study results on the company's H1N1 virus-like-particle pandemic influenza vaccine, forget the data indicated that NVAX's H1N1 VLP vaccine was well-tolerated and immunogenic.... Forget all that blasphemous news. Just look at the recent insider transactions
It's not a surefire guarantee of success. Earlier this year, General Maritime saw a bunch of insiders buy its stock (including the CFO), but its kept right on sinking. Yet Six Flags Entertainment experienced a big run up in its shares following its CFO's purchase, and while it has given back some of those peak gains, it still trades higher than it did and lends credence to it being a signal to watch.
You can watch Novavax by adding the antiviral maker's stock to the Fool's free portfolio tracker.
A certain disconnect
Doctors in Sweden were able to save a man's life by replacing his trachea -- blocked by a cancerous tumor -- with one grown in a laboratory using stem cells. The success of the operation, and the validity it shows residing in stem cell research, helped at least temporarily lift StemCells, Pluristem Technologies, and Geron
There seems to be a spate of good stem cell news, from a South African rugby player getting stem cell therapy treatment to doctors in Dallas curing back pain by injecting a patient's own stem cells to grow new bone, the technology continues to advance. And yet the stocks of many of the industry's leading names lag. Neostem's shares are down 56% for the year, StemCells is down 80% -- and Pluristem is up 80%!
There's always an outside chance that this company is simply doing what it has to in order to survive and prove their therapy actually works. Empirically however, virtually all stocks with this kind of history prove to be failures if not outright scams.
You can follow along by adding Pluristem to your your watchlist and have all the news and analysis about its progress aggregated in a single location.
What's wrong with that?
It pays to start your own research on these stocks on Motley Fool CAPS. Read a company's financial reports, scrutinize key data and charts, and examine the comments your fellow investors have made, all from a stock's CAPS page.
Sign up today for the completely free service, and tell us which side of the street will be the ultimate winner.